A Phase 3 clinical trial (NCT04657991) investigating pembrolizumab in combination with encorafenib and binimetinib for patients with advanced or metastatic melanoma reached its primary completion on 2026-01-12. This milestone indicates that the study has finished collecting data for its primary outcome measures.
Background
The study, titled "A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma," is evaluating a triple combination therapy. Pembrolizumab is an immunotherapy, while encorafenib and binimetinib are targeted therapies. The trial focuses on melanoma that is advanced or metastatic, has a specific BRAF gene abnormality, and has not received prior treatment.
Trial design
The Phase 3 study (NCT04657991) enrolled 257 participants with melanoma. The trial's purpose is to assess the effects of encorafenib, binimetinib, and pembrolizumab given together. All participants receive pembrolizumab via intravenous infusion every 3 weeks. Additionally, half of the participants receive oral encorafenib and binimetinib at home.
What this means
The primary completion of this Phase 3 trial signifies that the study has concluded the collection of data for its primary endpoints. This is a critical step in the drug development process, moving the trial closer to the analysis and potential release of results. The findings from this study could provide important insights into the efficacy and safety of this combination therapy for patients with advanced or metastatic BRAF-mutated melanoma, a population with significant unmet medical needs. Clinicians and researchers will await the full data analysis to understand the potential impact of this triple therapy regimen.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT04657991 was posted on 2026-01-12 on clinicaltrials.gov.